Merck/Bayer's Vericiguat Could Bring A New Dynamic For Heart Failure

The Phase III VICTORIA study evaluating the safety of the sGC stimulator met its primary endpoint.

Autumn red leaf with cut heart in a hand - Image
Vericiguat helped certain patients with chronic heart failure in a Phase III study • Source: Shutterstock

Merck & Co. Inc. and Bayer AG appear to have cleared a major hurdle with positive Phase III data in hand on its soluble guanylate cyclase (sGC) stimulator in development to treat patients with chronic heart failure with reduced ejection fraction (HFrEF). Merck announced on 18 November that the Phase III VICTORIA study evaluating the efficacy and safety of vericiguat met its primary endpoint.

The companies only released topline data from the trial, but said vericiguat reduced the risk of the composite endpoint in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

Pfizer’s Hympavzi Poised For Broader Hemophilia Label

 

The drugmaker announced positive topline results for the drug in hemophilia A and B patients with inhibitors, on top of the existing approval for patients without inhibitors.

BIO Finance Trends: Drug Developers Face Harsh Realities As Funding Constraints Continue

 
• By 

Financial markets were expected to loosen up in 2025, but BIO convention attendees indicated that conditions have worsened this year, so public and private firms are making tough choices.

Pharma Growth And Biotech Squeeze Will Shape Sector To 2030, Evaluate Forecasts

 

Evaluate’s five-year forecast sees steady growth for big pharma despite recent political turmoil but tougher times ahead for the ‘have nots’ of biotech.